Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis:A case reportOA
Delafloxacin(DLFX),a new anionic fluoroquinolone,has been approved by the United States Food and Drug Administration(FDA)and the European Medicines Agency(EMA)for the treatment of bacterial skin and skin structure infections and by the FDA for community-acquired pneumonia.This report describes a novel use of DFX as oral monotherapy in the treatment of staphylococcal prosthetic endocarditis.Prospective data would be useful to identify future opportunities for the use of this new fluoroquinolone in endocarditis both as monotherapy and for oral use,to simplify antibiotic regimen and to improve patients’quality of life and adherence to therapy.
Antonio Mastroianni;Valeria Vangeli;Giuliana Guadagnino;Luciana Chidichimo;Lavinia Berardelli;Sonia Greco
Infectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,ItalyInfectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,ItalyInfectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,ItalyInfectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,ItalyInfectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,ItalyInfectious&Tropical Diseases Unit,Azienda Ospedaliera di Cosenza,Annunziata Hub Hospital,Cosenza 87100,Italy
医药卫生
DelafloxacinEndocarditisStaphylococcus aureus
《Infectious Medicine》 2026 (1)
P.78-82,5
评论